Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Swanton

Showing results (241-250 of 440) with videos related to

Pageof 44
Sort By:
Nature Communications|April 15, 2020
Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axisCristina Morales Torres, Mary Y Wu, Sebastijan Hobor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2023
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid TumorsChristopher J Sweeney, John D Hainsworth, Ron Bose, et al.
Nature Genetics|March 7, 2020
Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolutionSaioa López, Emilia L Lim, Stuart Horswell, et al.
The Journal of Clinical Investigation|April 29, 2021
Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti-PD-1 therapyYeon Joo Kim, Katherine M Sheu, Jennifer Tsoi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2014
89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patientsSietske B M Gaykema, Carolien P Schröder, Joanna Vitfell-Rasmussen, et al.
The Lancet. Oncology|March 13, 2019
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket studyFunda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, et al.
Lancet (London, England)|January 23, 2022
Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patientsEdward J Carr, Mary Wu, Ruth Harvey, et al.
NAR Cancer|June 6, 2022
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assayFrancesco Orlando, Alessandro Romanel, Blanca Trujillo, et al.
Cancer Discovery|January 11, 2017
APC/C Dysfunction Limits Excessive Cancer Chromosomal InstabilityLaurent Sansregret, James O Patterson, Sally Dewhurst, et al.
The Journal of Pathology|October 15, 2013
Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomasMarco Gerlinger, Sergio A Quezada, Karl S Peggs, et al.
Pageof 44

Showing results (241-250 of 440) with videos related to

Sort By:
Pageof 44
Nature Communications|April 15, 2020
Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axisCristina Morales Torres, Mary Y Wu, Sebastijan Hobor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2023
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid TumorsChristopher J Sweeney, John D Hainsworth, Ron Bose, et al.
Nature Genetics|March 7, 2020
Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolutionSaioa López, Emilia L Lim, Stuart Horswell, et al.
The Journal of Clinical Investigation|April 29, 2021
Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti-PD-1 therapyYeon Joo Kim, Katherine M Sheu, Jennifer Tsoi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2014
89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patientsSietske B M Gaykema, Carolien P Schröder, Joanna Vitfell-Rasmussen, et al.
The Lancet. Oncology|March 13, 2019
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket studyFunda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, et al.
Lancet (London, England)|January 23, 2022
Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patientsEdward J Carr, Mary Wu, Ruth Harvey, et al.
NAR Cancer|June 6, 2022
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assayFrancesco Orlando, Alessandro Romanel, Blanca Trujillo, et al.
Cancer Discovery|January 11, 2017
APC/C Dysfunction Limits Excessive Cancer Chromosomal InstabilityLaurent Sansregret, James O Patterson, Sally Dewhurst, et al.
The Journal of Pathology|October 15, 2013
Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomasMarco Gerlinger, Sergio A Quezada, Karl S Peggs, et al.
Pageof 44